CREB-binding protein (CBP, CREBBP) and the closely related E1A-binding protein p300 (EP300) are transcriptional coactivators that interact physically or functionally with about 10 percent of the estimated 2,000 mammalian transcriptional regulatory proteins. Both genes are required for normal development and physiology, and altered-function- and inactivating-mutations occur in cancer, indicating that CBP and p300 can function both as oncoproteins and as tumor suppressors. Several major unresolved questions remain with regard to the biological and transcriptional roles of CBP and p300. First, it is largely unknown what roles the multiple different transcription factor-binding domains of CBP and p300 play in development and tumorigenesis in vivo. Second, many in vitro studies indicate that CBP and p300 are biochemically indistinguishable, but it is uncertain how redundant their functions are in vivo. Third, numerous in vitro transcription studies have shown that CBP and p300 are crucial coactivators, yet little is known regarding their roles in endogenous gene expression. Fourth, it is uncertain if different classes of coactivators function redundantly. These questions form the core of the application's broad, long-term, objectives, aspects of which will be approached by testing the in vivo functions of two specific protein-binding domains common to CBP and p300. Four strains of knock-in mutant mice have been generated. Two have point mutations on the surface of the KIX domain of CBP and p300 that inhibits the binding of the cAMP-responsive factor CREB and the hematopoietic factor c-Myb, and two strains that have a deletion mutation in the CH1 domain of CBP and p300 that abrogates the binding of the hypoxia-responsive factor HIF-1.
Three specific aims will be pursued using these mice.
Aim 1 is to elucidate the roles of the KIX domain of CBP and p300 in vivo.
Aim 2 is to determine the roles of the CH1 domain of CBP and p300 in vivo.
Aim 3 is to establish if CBP and p300 are biochemically redundant in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
High Priority, Short Term Project Award (R56)
Project #
2R56DK058199-05
Application #
7036438
Study Section
Molecular and Cellular Endocrinology Study Section (MCE)
Program Officer
Margolis, Ronald N
Project Start
2000-07-01
Project End
2006-05-31
Budget Start
2005-06-01
Budget End
2006-05-31
Support Year
5
Fiscal Year
2005
Total Cost
$75,000
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Bedford, David C; Kasper, Lawryn H; Wang, Ruoning et al. (2011) Disrupting the CH1 domain structure in the acetyltransferases CBP and p300 results in lean mice with increased metabolic control. Cell Metab 14:219-30
Kasper, Lawryn H; Boussouar, Faycal; Boyd, Kelli et al. (2005) Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. EMBO J 24:3846-58